QIAGEN N.V. (QGEN) stock
QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$49.75−0.06 (-0.12%)
Close on Nov 17, 2026Market cap $10.79BP/E 25.6Yield 0.50%
Qiagen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $1.94, up 424.3% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $2.21 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94 | +424.3% |
| FY2024 | Dec 31, 2024 | $0.37 | -75.0% |
| FY2023 | Dec 31, 2023 | $1.48 | -19.6% |
| FY2022 | Dec 31, 2022 | $1.84 | -16.7% |
| FY2021 | Dec 31, 2021 | $2.21 | +44.4% |
| FY2020 | Dec 31, 2020 | $1.53 | – |
| FY2019 | Dec 31, 2019 | -$0.18 | -122.0% |
| FY2018 | Dec 31, 2018 | $0.82 | +382.4% |
| FY2017 | Dec 31, 2017 | $0.17 | -50.0% |
| FY2016 | Dec 31, 2016 | $0.34 | -38.2% |
| FY2015 | Dec 31, 2015 | $0.55 | +14.6% |
| FY2014 | Dec 31, 2014 | $0.48 | +65.5% |
| FY2013 | Dec 31, 2013 | $0.29 | -46.3% |
| FY2012 | Dec 31, 2012 | $0.54 | +35.0% |
| FY2011 | Dec 31, 2011 | $0.40 | -33.3% |
| FY2010 | Dec 31, 2010 | $0.60 | -6.3% |
| FY2009 | Dec 31, 2009 | $0.64 | +45.5% |
| FY2008 | Dec 31, 2008 | $0.44 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?